Skip to main content

Table 2 Baseline clinical and health factors of patients initiating ART by coinfection in four high-burden hospitals in Addis Ababa, Ethiopia (September 2011 to December 2018), n = 646

From: Retention on antiretroviral therapy in person with HIV and viral hepatitis coinfection in Ethiopia: a retrospective cohort study

Characteristics n (%) of participants
HIV Monoinfection HIV Coinfection
CD4 cell count/mm3 (n = 602)
 Median (IQR) 181(97–310) 183(87–318)
  < 200 263(54.68) 63(52.07)
  200–350 129(26.82) 34(28.10)
  > 350 89(18.50) 24(19.83)
WHO staging (n = 639)
  I & II 248(48.72) 57(43.85)
  III & IV 261(51.28) 73(56.15)
Functional status (n = 635)
  Bedridden 81(15.98) 16(12.50)
  Ambulatory 26(5.12) 8(6.25)
  Working 400(78.90) 104(81.25)
bTuberculosis (TB) presence at baseline
 Yes 168(32.71) 17(13.71)
 No 346(67.32) 107(86.29)
Opportunistic infection (OI) at baseline, n = 514
 Yes 201(39.11) 74(56.06)
  No 313(60.89) 58(43.94)
Median hemoglobin (IQR) (n = 474) 13(11.4–14.5) 13.9(12.1–15.1)
b Median AST (IQR) (n = 549) 30.5(22–45) 36(26–53.5)
b Medina ALT (IQR) (n = 508) 23(16–38) 28(18–44)
b Median Platelet (IQR) (n = 260) 242(198–315) 185(151–218)
  1. HIV-Monoinfection: negative for both hepatitis B virus and hepatitis C viruses; HIV-Coinfection: hepatitis B virus or hepatitis C virus positive; IQR interquartile range, WHO World Health Organization, ALT alanine transaminase, AST aspartate aminotransferase; b Indicates significant difference between the HIV-coinfected and HIV-monoinfected groups with a p-value < 0.05